All News
Expanding Global Biosimilar Market
Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.
Read ArticleKnee Implant Forecast from 2012 - 2018
The global knee implants market was USD 8.4 billion in 2011, and it's forecasted to reach USD 15 billion in 2018, with compound annual growth rate of 8.64% during 2011 to 2018. The U.S.
Read ArticleNonadherence to Self-Injected Biologics is High
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Read ArticleMedicare D and Costly Biologics
25% of Medicare beneficiaries with rheumatoid arthritis use high-cost biologics. Yazdany and coworkers have analyzed a national cohort of beneficiaries and compared Medicare part D plans.
Read ArticleUnderuse & Overuse of DXA Screening
A US Preventive Services Task Force recommends DEXA screening in women >65 yrs and only in women 65 yrs if there is a significan risk of fracture. Amarnath and coworkers studied 50,995 women in primary care, aged 40-85 years, between 2006-2012.
Read ArticleAmgen & Abbvie Increase the Price of TNF Inhibitors
The manufacturers of the 2 best selling TNF inhibitors, Enbrel and Humira, have announced a 9.9% price increase of May 1st. The current average price of Enbrel is $42,000 per annum.
Read Article
Economic Impact of Biosimilars
According to the Federal Trade Commission biosimilars have the potential to save the U.S. healthcare system $250 billion through 2022.
Read ArticleRA Compliance Undermines Treatment Success
Researchers at MD Anderson Cancer Center in Houston prospectively studied 107 RA patients with regard to oral medication (DMARDs, steroids) adherence. They report that adherence was low, ranging from 58-71% overall.
Read ArticleMost Prescribed Branded Drugs Through March 2015
In the last 12 months, levothyroxine (Synthroid) was the most prescribed drug in the USA with 21.6 million prescriptions. Adalimumab (Humira) had 8.3 billion in sales, followed by etanercept (Enbrel) at nearly $6 billion.
Read Article
Medicare Spends $2.5 billion on Prescription Nexium in 2013
Medicare released its list of the most costly medicines presribed in 2013.
Read Article